Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $16.78, but opened at $17.26. Daiichi Sankyo shares last traded at $16.9550, with a volume of 9,411 shares traded.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the stock. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.
Check Out Our Latest Stock Report on DSNKY
Daiichi Sankyo Trading Up 0.9%
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities research analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 earnings per share for the current year.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
Featured Stories
- Five stocks we like better than Daiichi Sankyo
- Home Depot Analysts See a Path to $375 and Beyond
- RTX Stock Gets a Radar Lock on a $23B Navy Win
- Berkshire Just Made a Huge Alphabet Bet—Should You Follow?
- Michael Burry Is Betting Against Palantir Again—Should Investors Care?
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
